

In the claims:

1. (Currently amended) A method of identifying interactions between polypeptides comprising:

- (a) separately expressing in a ~~host-cell~~ ~~substantially-lacking~~ Ras activity:
  - (i) a first polynucleotide encoding a first polypeptide being capable of interacting with a plasmalemma of the cell; and
  - (ii) a second polynucleotide encoding a second polypeptide fused to a cytoplasmic Ras mutant, said cytoplasmic Ras mutant being capable of said Ras activity if mobilized to said plasmalemma of said cell; and
- (b) detecting ~~a presence or absence of said~~ Ras activity in said cell in the presence and absence of expression of said first polypeptide, wherein said Ras activity present only with expression of said first polypeptide is being indicative of ~~a possible an~~ interaction between said first polypeptide and said second polypeptide.

2. (Original) The method of claim 1, wherein said first polypeptide is a native membrane protein.

3-5. (Cancelled)

6. (Currently amended) The method of claim 1, wherein said cell ~~substantially-lacking~~ Ras activity is a yeast cell exhibiting a mutant Ras phenotype characterized by growth suppression under non-permissive conditions.

7. (Original) The method of claim 6, wherein said cytoplasmic Ras mutant is capable of complementing said mutant Ras phenotype if mobilized to said plasmalemma of said cell.

8. (Original) The method of claim 1, wherein said first polypeptide includes an amino acid sequence for plasmalemma targeting.

9. (Currently amended) A method of identifying interactions between polypeptides comprising:

- (a) separately expressing in cells ~~substantially-lacking a~~ Ras activity:
  - (i) a first polynucleotide encoding a first polypeptide being capable of interacting with a plasmalemma of said cells; and
  - (ii) a library of polynucleotides each encoding a distinct polypeptide fused to fused to a cytoplasmic Ras mutant, said cytoplasmic Ras mutant being capable of said Ras activity if mobilized to said plasmalemma of said cells; and
- (b) identifying a subset of cells exhibiting said Ras activity in said cells in the presence and absence of expression of said first polypeptide, wherein said Ras activity present only with expression of said first polypeptide is being indicative of ~~a possible~~ interaction between said first polypeptide and ~~said~~ a distinct polypeptide expressed in said ~~subset of cells~~.

10. (Currently amended) The method of claim 9, further comprising isolating from each cell of said ~~subset of cells~~ a polynucleotide encoding said distinct polypeptide.

11. (Original) The method of claim 9, wherein said first polypeptide is a native membrane protein.

12-14. (Cancelled)

15. (Currently amended) The method of claim 9, wherein said cells ~~substantially-lacking~~ said Ras activity are yeast cells exhibiting a mutant Ras phenotype characterized by growth suppression under non-permissive conditions.

16. (Original) The method of claim 15, wherein said cytoplasmic Ras mutant is capable of complementing said mutant Ras phenotype if mobilized to said plasmalemma of said cells.

17. (Original) The method of claim 9, wherein said first polypeptide includes an amino acid sequence for plasmalemma targeting.

18. (Currently amended) A method of identifying interactions between polypeptides comprising:

- (a) separately expressing in cells-substantially lacking a Ras activity:
  - (i) a library of polynucleotides each encoding a first polypeptide being capable of interacting with a plasmalemma of said cells fused to a second polypeptide; and
  - (ii) a second polynucleotide encoding a cytoplasmic Ras mutant fused to a third polypeptide, said cytoplasmic Ras mutant being capable of said Ras activity if mobilized to said plasmalemma of said cells; and
- (b) identifying-a-subset-of-cells-exhibiting-said-Ras activity in said cells in the presence and absence of expression of said first polypeptide, wherein, said Ras activity present only with expression of said first polypeptide beingis indicative of a-possiblean interaction between said third polypeptide and said second polypeptide expressed in each cell of said subset-of-cells.

19 (Currently amended) The method of claim 18, further comprising isolating from each cell of said ~~subset-of-cells~~ a polynucleotide encoding said second polypeptide.

20. (Original) The method of claim 18, wherein said first polypeptide is a native membrane protein.

21-23. (Cancelled)

24. (Currently amended) The method of claim 18, wherein said cells ~~substantially-lacking~~ said Ras activity are yeast cells exhibiting a mutant Ras phenotype characterized by growth suppression under non-permissive conditions.

25. (Original) The method of claim 24, wherein said cytoplasmic Ras mutant is capable of complementing said mutant Ras phenotype if mobilized to said plasmalemma of said cells.

26. (Original) The method of claim 18, wherein said first polypeptide includes an amino acid sequence for plasmalemma targeting.

27 (Currently amended) A method of identifying interactions between polypeptides comprising:

- (a) separately expressing in cells ~~substantially-lacking~~ a Ras activity:
  - (i) a first library of polynucleotides each encoding a first polypeptide being capable of interacting with a plasmalemma of said cells fused to a second polypeptide; and
  - (ii) a second library of polynucleotides each encoding a cytoplasmic Ras mutant fused to a third polypeptide, said cytoplasmic Ras mutant being capable of said Ras activity if mobilized to said plasmalemma of said cells; and
- (b) identifying ~~a subset of cells exhibiting~~ said Ras activity in said cells in the presence and absence of expression of said first polypeptide, wherein said Ras activity ~~being-is~~ indicative of a ~~possible~~ lean interaction between said third polypeptide and said second polypeptide expressed in each cell of said ~~subset of cells~~.

28. (Currently amended) The method of claim 27, further comprising isolating from each cell of said ~~subset of cells~~ polynucleotides encoding said second polypeptide and said third polynucleotides.

29. (Original) The method of claim 27, wherein said first polypeptide is a native membrane protein.

30-32. (Cancelled)

33. (Currently amended) The method of claim 27, wherein said cells ~~substantially-lacking~~ said Ras activity are yeast cells exhibiting a mutant Ras phenotype characterized by growth suppression under non-permissive conditions.

34. (Original) The method of claim 33, wherein said cytoplasmic Ras mutant is capable of complementing said mutant Ras phenotype if mobilized to said plasmalemma of said cells.

35. (Original) The method of claim 27, wherein said first polypeptide includes an amino acid sequence for plasmalemma targeting.

36. (Withdrawn) A nucleic acid construct comprising a polynucleotide encoding a cytoplasmic Ras mutant under the transcriptional control of an inducible promoter.

37. (Withdrawn) The nucleic acid construct of claim 36, wherein said inducible promoter is functional in eukaryotic cells.

38. (Withdrawn) The nucleic acid construct of claim 36, wherein said inducible promoter is selected from the group consisting of a Gal1 promoter, a Yes2 promoter, a Met425 promoter and a copper inducible promoter.

39. (Withdrawn) A nucleic acid construct library comprising a plurality of nucleic acid constructs each including a first polynucleotide region encoding a cytoplasmic Ras mutant translationally fused to a second polynucleotide region encoding a distinct polypeptide.

40. (Withdrawn) The nucleic acid construct library of claim 39, wherein each of said plurality of nucleic acid constructs further includes a promoter for directing the expression of said first and said second polynucleotide regions.

41. (Withdrawn) The nucleic acid construct library of claim 40, wherein said promoter is functional in eukaryotic cells.

42. (Withdrawn) The nucleic acid construct library of claim 40, wherein said promoter is an inducible promoter selected from the group consisting of a Gal1 promoter, a Yes2 promoter, a Met425 promoter and a copper inducible promoter.

43. (Withdrawn) A nucleic acid construct system comprising:

- (a) a first nucleic acid construct including a first polynucleotide encoding a first polypeptide being capable of interacting with a plasmalemma of a cell in which it is expressed; and
- (b) a second nucleic acid construct including a second polynucleotide encoding a cytoplasmic Ras mutant fused to a second polypeptide.

44. (Withdrawn) The nucleic acid construct system of claim 43, wherein said first and said second nucleic acid construct each further include a promoter sequence for directing an expression of said first and said second polynucleotides in a eukaryotic cell.

45. (Withdrawn) The nucleic acid construct system of claim 44, wherein said first nucleic acid construct includes a first promoter sequence and said second nucleic acid construct includes a second promoter sequence, whereas said first and said second promoter sequences are independently selected from the group consisting of a constitutive promoter sequence and an inducible promoter sequence.

46. (Withdrawn) The nucleic acid construct system of claim 45, wherein said inducible promoter sequence is selected from the group consisting of a Gal1 promoter, a Yes2 promoter, a Met425 promoter and a copper inducible promoter.

47. (Withdrawn) A method of identifying polypeptides of interest comprising:

- (a) expressing in a cell substantially lacking Ras activity:
  - (i) a first polynucleotide encoding a first polypeptide being capable of modifying a plasmalemma of the cell; and
  - (ii) a second polynucleotide encoding a second polypeptide fused to a cytoplasmic Ras mutant, said cytoplasmic Ras mutant being capable of said Ras activity if mobilized to said plasmalemma of said cell; and
- (b) detecting a presence or absence of said Ras activity in said cell, said Ras activity being indicative of membrane mobilization of said second polypeptide resultant from a modification to said plasmalemma effected by said first polypeptide.

48. (Withdrawn) The method of claim 47, wherein said modifying said plasmalemma of the cell is effected by modifying a protein or phospholipid component of said plasmalemma.

49. (Withdrawn) The method of claim 47, wherein said first polypeptide is PI3kinase.